FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like BioCorp Release: Company To Present Its Innovations At On 1st-2nd February 2017 In Paris January 24, 2017 GW Pharma, Otsuka Satvex Deal Terminated December 12, 2017 Natus Medical Pays $48 Million for Integra LifeSciences' Neurosurgery Assets September 11, 2017
BioCorp Release: Company To Present Its Innovations At On 1st-2nd February 2017 In Paris January 24, 2017
